Novartis Pharma B.V.

Location

Noord-Holland

Founded

1948-02-10

Risk Signals

21161 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Recent Articles about Novartis Pharma B.V.

Live alerts from global media, monitored by Business Radar

5 people charged in $600K insider trading scheme tied to Novartis' Chinook acquisition: DOJ

2025-05-27 (fiercebiotech.com)

5 people charged in $600K insider trading scheme tied to Novartis' Chinook acquisition: DOJ

Five people have been charged for allegedly participating in an insider trading scheme tied to

Read more
Ser­no­va chair re­signs fol­low­ing in­sid­er trad­ing in­dict­ment over No­var­tis-Chi­nook deal

2025-05-27 (endpts.com)

Ser­no­va chair re­signs fol­low­ing in­sid­er trad­ing in­dict­ment over No­var­tis-Chi­nook deal

Sernova chairman Ross Haghighat resigns after DOJ indictment on 16 insider trading counts related to Novartis' $3.2B Chinook Therapeutics acquisition in 2023.

Read more
Biotech Insider Traded On $3.5B Novartis Deal, Feds Say -

2025-05-24 (law360.com)

Biotech Insider Traded On $3.5B Novartis Deal, Feds Say -

A former board member at Chinook Therapeutics orchestrated an insider-trading scheme after learning about Novartis' plans to purchase the biotech company for $3.5 billion in 2023, according to an indictment announced Friday.

Read more
Novartis, Genentech Lose Asthma Drug Patent In Netherlands -

2025-03-31 (law360.co.uk)

Novartis, Genentech Lose Asthma Drug Patent In Netherlands -

Celltrion Inc. has persuaded a Dutch court to revoke Novartis and Genentech's patent in the Netherlands for asthma drug omalizumab, straying from a London judge's recent decision to uphold the U.K. part of the patent.

Read more
Insider Decision Unfolding At Incyte: Matteo Trotta Exercises Options, Resulting In $0 - Incyte (NASDAQ:INCY) -

2025-01-24 (benzinga.com)

Insider Decision Unfolding At Incyte: Matteo Trotta Exercises Options, Resulting In $0 - Incyte (NASDAQ:INCY) -

A significant insider transaction involving the exercise of company stock options was reported on January 22, by Matteo Trotta, EVP at Incyte INCY, as per the latest SEC filing.

Read more
Zurich stock exchange and Europe in the red: SLI and STOXX 50 weaken on Thursday afternoon

2024-10-03 (aktien-und-etf.de)

Zurich stock exchange and Europe in the red: SLI and STOXX 50 weaken on Thursday afternoon

The Zurich stock exchange and Europe's STOXX 50 posted losses at midday on Thursday, while a Briton made millions for insider trading with hacked knowledge.

Read more
Press review from weekend 28 (08/09 July)

2023-07-09 (finanzen.ch)

Press review from weekend 28 (08/09 July)

Zurich (awp) - Below is a selection of articles on business-related topics from the press over the weekend: SNB: According to the SNB, the banks...

Read more
Medela Concludes Global Breastfeeding Symposium with Key Takeaways in Lactation Science to Inform Clinical Practice

2023-06-27 (finanzen.ch)

Medela Concludes Global Breastfeeding Symposium with Key Takeaways in Lactation Science to Inform Clinical Practice

Leading Breast Pump Brand Hosts Global Event to Advance Breastfeeding Research and Understand Current Hospital-Based Practices, Sharing Research F...

Read more
FDA Inspection Blitz Leads to More Than 180 Warning Letters to Retailers for the Illegal Sale of Youth-Appealing Elf Bar and Esco Bars E-Cigarettes

2023-06-22 (finanzen.ch)

FDA Inspection Blitz Leads to More Than 180 Warning Letters to Retailers for the Illegal Sale of Youth-Appealing Elf Bar and Esco Bars E-Cigarettes

Calls to Poison Centers About Elf Bar Exposure Among Children Under 5 Raise Concerns SILVER SPRING, Md., June 22, 2023 /PRNewswire/ -- Today, the U...

Read more
With these Swiss shares, the cash Insider enters 2023

2022-12-29 (cash.ch)

With these Swiss shares, the cash Insider enters 2023

The cash Insider reveals which ten Swiss stocks he is going into the new stock market year with. There are some surprising changes. Unlike a year ago, the stock market forecasts of the banks and their strategists are pretty gloomy. Those of the goods in the last few weeks and months

Read more
Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court |

2022-09-21 (fiercepharma.com)

Facing 'imminent' Gilenya generics and a $300M sales hit, Novartis takes patent fight to Supreme Court |

After back-to-back setbacks in its high-stakes Gilenya patent defense, Novartis is taking its arguments all the way to the Supreme Court. | After the U.S. Court of Appeals rejected its bid to rehear a negative decision on its Gilenya patent, Novartis will turn to the Supreme Court to defend its patent against generics.

Read more
Novartis hit with Entresto patent suit from universities amid legal fight with generics makers

2022-08-30 (fiercepharma.com)

Novartis hit with Entresto patent suit from universities amid legal fight with generics makers

Novartis is already suing a long list of generics producers that aim to bring copycats of the company's popular heart failure drug Entresto to market. | Novartis is already suing a long list of generics producers that aim to bring copycats of the Swiss pharma's popular heart failure drug Entresto to market. Now, the company itself has become target in a patent infringement lawsuit.

Read more

Never miss a headline about Novartis Pharma B.V.

Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story.

  • ✔️ Used by 100+ compliance teams and analysts
  • ✔️ Covers 154M+ sources in 40+ languages